Printer Friendly

MERCK'S WEST POINT PHARMA WILL EXPAND ITS LINE OF GENERIC PRODUCTS

 WEST POINT, Pa., April 12 /PRNewswire/ -- Merck & Co. Inc. (NYSE: MRK) announced today it will soon expand the number of generic products currently available through its West Point Pharma Division.
 West Point Pharma introduced its first product in October 1992: a generic version of Dolobid(R) (diflunisal), which is indicated for acute or long-term use for treatment of mild to moderate pain, osteoarthritis and rheumatoid arthritis.
 Merck reported that West Point Pharma's generic formulation of diflunisal exceeded expectations in 1992, accounting for approximately one-half of the dispensed prescriptions for generic diflunisal.
 West Point Pharma will begin marketing more than 25 different packages and dosages of generic versions of 10 additional off-patent brands. The specific products will be announced as they are introduced over the next four months.
 The company said expanding its line of generic products at this time will enable it to offer a product line that will meet a need expressed by many of its customers for efficacious products that are also cost- effective. According to West Point Pharma General Manager Ed Jeglum, virtually all customer segments -- especially those in the managed health care area -- have embraced Merck's initial generic entry and have actively expressed interest in an expanded product offering.
 Sales support for the expansion will be provided by HMS Sales and Marketing, of Jacksonville, Fla.
 Merck said the revenues from its generic line will provide additional support to the discovery of new medications that will extend and improve human life. The company spent more than $1.1 billion on research and development in 1992.
 Merck is a worldwide, research-intensive health products company that discovers, develops, produces and markets human and animal health products and specialty chemicals.
 Dolobid is the Merck registered trademark for diflunisal.
 /delval/
 -0- 4/12/93
 /CONTACT: Jan D. Weiner (media), 215-652-6462, or Dave Halter (investors), 908-423-6883, both of Merck/
 (MRK)


CO: Merck & Co. Inc.; West Point Pharma ST: Pennsylvania, Florida IN: MTC SU: PDT

MP-LJ -- PH002 -- 4646 04/12/93 09:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:331
Previous Article:SALVADORE NAMED VP - OPERATIONS FOR J&L SPECIALTY PRODUCTS
Next Article:SHARP ELECTRONICS CORP. ANNOUNCES 64K BY 18-BIT STATIC RAM WITH LOW NOISE, 20-35 NANOSECOND ACCESS TIME
Topics:


Related Articles
THE DUPONT MERCK PHARMACEUTICAL COMPANY FORMS A NEW GENERIC COMPANY, ENDO LABORATORIES L.L.C. AND NAMES CAROL A. AMMON PRESIDENT
DUPONT PHARMA RADIOPHARMACEUTICALS TO ACQUIRE MARKETING ASSETS OF MEDGENIX DIAGNOSTICS RADIOPHARMACEUTICALS IN EUROPE
Endo Pharmaceuticals Inc. Forms Separate Divisions For Brand and Generic Products
New Coumadin(R) Package Insert Warns Against Duplicate Dosing
Pharmaceutical Resources Announces the Approval of Methimazole.
Merck KGaA Sells Minority Stake in Pharmaceutical Resources for More Than EUR 400 million.
MERCK KGAA SELLS MINORITY STAKE IN PHARMACEUTICAL RESOURCES FOR MORE THAN EUR 400 MILLION.
Big pharma R&D operations make changes.
Astellas Pharma Obtains Preliminary Injunctions Against Generic Companies in Germany.
Astellas Sues Spanish Generic Companies for Infringement of Patent on Omnic(R) Capsule.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters